Malvern Specialist to Explore use of Nanoparticle Tracking Analysis for Characterising Extracellular Vesicles at ISEV 2014
Pauline Carnell, Senior Application Scientist at Malvern Instruments, will present a paper at ISEV 2014 discussing ‘The practical use of nanoparticle tracking analysis (NTA) to characterise extracellular vesicles in general and when using fluorescence markers’.
ISEV 2014 is a meeting of the International Society for Extracellular Vesicles. It takes place in Rotterdam, The Netherlands, from 30 April to 3 May 2014, with an education day on 29 April. Pauline Carnell will present the paper, co-authored with colleagues Andrew Malloy, Agnieszka Siupa, Patrick Hole and Bob Carr, on 30 April. All the authors are experts in the technology and application of NanoSight Nanoparticle Tracking Analysis (NTA).
NanoSight NTA systems are now offered as part of Malvern’s portfolio of analytical solutions for characterisation at the nanoscale.
Extracellular vesicles, typically 30–100 nm, are released within and from a wide variety of cells. They are increasingly implicated and appear in a multitude of pathological conditions and show much promise as diagnostics for many different diseases including cancer, heart disease, diabetes, Alzheimer's and pre-eclampsia. However, developments in this area are constrained by limitations in the technology available for their measurement.
NanoSight Nanoparticle Tracking Analysis offers the potential to rapidly enumerate and speciate these particles. In this method the particles in suspension scatter laser light, which is collected by a CCD (or sCMOS) camera via a microscope-type configuration. Particles are tracked individually and their diffusion coefficient, and therefore size, calculated directly from their speed. This gives a direct measurement of the concentration and size distribution of the particles in the field of view.
Fluorescent labelling of particles for expressed markers enables measurement of the concentration and size distribution of those labelled particles only, allowing the proportion of labelled particles to be calculated. Pauline Carnell’s presentation will examine some of the challenges and considerations required during protocol development and measurement, and will include examples of good methodologies and appropriate controls.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.